1 not yet recruiting, 1 unknown. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 1, Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Best Available Therapy (BAT): new trials by email Literature Review of Best Available Therapy (BAT) trials Research Report on Best Available Therapy (BAT)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex BV100 with 50 mg polymyxin B plus ceftazidime/avibactam, BV100 with 50 mg polymyxin B plus cefiderocol, Best Available Therapy (BAT) - Ventilator Associated Bacterial Pneumonia (VABP), Hospital Acquired Bacterial Pneumonia (HABP) | Phase 2 | Not yet recruiting | BioVersys AG | 120 | 2026-07-01 | 2026-02-24 |
| KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment KRT-232, Best Available Therapy (BAT) - Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF) | Phase 2 / Phase 3 | Unknown | Kartos Therapeutics, Inc. | 385 | 2019-01-15 | 2023-04-28 |
Central Nervous System Infections (1) · Cerebral Ventriculitis (1) · Meningitis, Bacterial (1) · Primary Myelofibrosis (1)
BioVersys AG (1) · Kartos Therapeutics, Inc. (1)
Argentina (1) · Australia (1) · Brazil (1) · Bulgaria (1) · Canada (1) · Croatia (1) · Czechia (1) · France (1) · Germany (1) · Greece (1) · Hong Kong (1) · Hungary (1) · Israel (1) · Italy (1) · Lithuania (1)